Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06077903

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Sponsor: Grit Biotechnology

Conditions Adult

Interventions GT101

Updated 4 times since 2023 Last updated: Feb 19, 2025 Started: Jul 5, 2021 Primary completion: Jul 31, 2025 Completion: Jul 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06077903, this EARLY_PHASE1 trial focuses on Adult and remains actively recruiting participants. Sponsored by Grit Biotechnology, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Mar 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Sep 2024 — Mar 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Nov 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Grit Biotechnology

Data source: Grit Biotechnology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China